ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in Columbus, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Food Hypersensitivity
Hidradenitis
Hidradenitis Suppurativa
Hypersensitivity
Pruritus

Eczema trials near Columbus, OH, USA:

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to \<12 yea...

Enrolling
Eczema
Drug: Abrocitinib
Other: Placebo

Phase 3

Pfizer
Pfizer

Columbus, Ohio, United States and 12 other locations

The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

Enrolling
Atopic Dermatitis Eczema
Eczema
Drug: Placebo
Drug: IMG-007

Phase 2

Inmagene

Columbus, Ohio, United States of America and 8 other locations

The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...

Active, not recruiting
Atopic Dermatitis
Drug: Dupilumab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Gahanna, Ohio, United States and 83 other locations

The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have...

Active, not recruiting
Dermatitis, Atopic
Drug: GSK1070806

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Dublin, Ohio, United States and 52 other locations

This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK10...

Active, not recruiting
Dermatitis, Atopic
Drug: GSK1070806
Drug: Placebo

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Dublin, Ohio, United States and 91 other locations

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Phase 3

Pfizer
Pfizer

Columbus, Ohio, United States and 536 other locations

This is a study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered KT-621 in adult ma...

Enrolling
Atopic Dermatitis
Drug: KT-621

Phase 1

Kymera Therapeutics

Dublin, Ohio, United States and 11 other locations

The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic...

Enrolling
Atopic Dermatitis
Drug: Afimkibart
Drug: Placebo

Phase 2

Roche
Roche

Dublin, Ohio, United States and 33 other locations

The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneously using devices for injection.

Active, not recruiting
Atopic Dermatitis
Combination Product: Rocatinlimab AI
Combination Product: Rocatinlimab Prefilled Syringe

Phase 3

Amgen
Amgen

Bexley, Ohio, United States of America and 46 other locations

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

Phase 3

Amgen
Amgen

Bexley, Ohio, United States of America and 546 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems